ArticlePharmaceuticals (Basel, Switzerland)2021

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study.

Steven Simoens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.